GlassScriptPhysician profile
Patrick Tobbia
NPI 1427362011
$13,602.63
in general payments reported to CMS, 2019-2025
36 companies · $4,764 in 2025
The $4,764 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $349 · 2021: $869 · 2022: $885 · 2023: $5,371 · 2024: $705 · 2025: $4,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,791 · Food and Beverage: $5,028 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,791.39 |
| Food and Beverage | $5,028.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,812.99 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $1,752.04 | 2019-2025 | Versacross Access Solution, Avvigo Guidance System, Watchman Flx |
| Medtronic, INC. | $1,620.21 | 2021-2025 | Corevalve Evolut R, Launcher, Symplicity G3 |
| Abbott Laboratories | $1,499.54 | 2019-2025 | Aveir, Amplatzer Talisman, Navitor |
| W. L. Gore & Associates, INC. | $1,380.52 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Abiomed | $545.02 | 2021-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $399.57 | 2019-2025 | |
| Shockwave Medical, INC | $348.88 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $307.17 | 2019-2025 | Lifevest |
| Pfizer INC. | $223.16 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $203.66 | 2021-2025 | Fluency Endovascular Stent Graft |
| Merck Sharp & Dohme LLC | $182.15 | 2022-2025 | Verquvo |
| Amgen INC. | $122.89 | 2019-2023 | Repatha |
| Novo Nordisk INC | $119.71 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $119.65 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.81 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $110.41 | 2019-2025 | Farxiga, Lokelma |
| Philips North America LLC | $98.12 | 2019-2025 | Ecc Solutions, (Ck7) Extended Holter |
| Cardiva Medical, INC. | $86.56 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Asahi Intecc USA, INC. | $85.64 | 2022-2025 | Peripheral Vascular, Asahi Coronary Wires, Asahi Peripheral Vascular Wires |
| Janssen Pharmaceuticals, INC | $82.55 | 2022-2024 | Xarelto |
| Baxter Healthcare | $42.26 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $39.17 | 2023-2024 | |
| Gilead Sciences, INC. | $37.80 | 2019 | |
| Elutia, INC. | $34.20 | 2020-2021 | |
| Bardy Diagnostics, INC. | $31.81 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.77 | 2019-2024 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $26.10 | 2019 | |
| Irhythm Technologies, INC. | $24.04 | 2024 | Zio Monitor, Zio Xt Patch |
| Avinger INC. | $21.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Teleflex LLC | $18.37 | 2019 | |
| Amarin Pharma, INC. | $16.81 | 2020 | |
| Heartflow, INC. | $15.42 | 2025 | |
| Esperion Therapeutics, INC. | $14.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tobbia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.